Compare Stocks

→ A.I. Pioneer Issues Urgent Warning to Americans (From TradeSmith) (Ad)

Compare stocks and their fundamentals, performance, price, and technicals. Use this free stock comparison tool to evaluate companies based on their analyst ratings, book value, debt, dividend, MarketRank, news sentiment, price performance, profitability, and more. Enter up to ten stock symbols separated by a comma or space (ex. BAC, JPM, WFC, C, GS).

Comparative Price Performance Over Time

Compare Stocks - Price & Volume

Company	Current Price	50-Day Moving Average	52-Week Range	Market Cap	Beta	Avg. Volume	Today's Volume
DMAC DiaMedica Therapeutics	$2.52 -3.1%	$2.86	$1.50 ▼ $4.75	$95.66M	1.69	42,659 shs	5,903 shs
EVFM Evofem Biosciences	$0.02 +14.7%	$0.02	$0.01 ▼ $4.36	$842K	-1.12	788,459 shs	102,252 shs
REPH Recro Pharma		$1.73	$1.38 ▼ $3.79	$117.93M	1.08	126,298 shs	141,800 shs
RTTR Ritter Pharmaceuticals	$0.30 -0.8%	$2.99	$0.15 ▼ $1.27	$13.73M	-0.43	14.23 million shs	47,891 shs
ZSAN Zosano Pharma	$0.00	$3.90	$0.46 ▼ $37.45	$1K	3.3	425,375 shs	5,685 shs

Investing Strategies To Help Grow Your Retirement Income

Need to stretch out your 401K or Roth IRA plan? Use these time-tested investing strategies to grow the monthly retirement income that your stock portfolio generates.

Get This Free Report

Price Performance

Company	1-Day Performance	7-Day Performance	30-Day Performance	90-Day Performance	1-Year Performance
DMAC DiaMedica Therapeutics	+9.70%	-1.89%	-8.77%	-8.77%	+60.49%
EVFM Evofem Biosciences	-11.11%	-24.02%	-27.19%	-65.13%	-99.60%
REPH Recro Pharma	0.00%	0.00%	0.00%	0.00%	0.00%
RTTR Ritter Pharmaceuticals	-0.80%	-21.74%	-17.62%	-40.58%	-70.41%
ZSAN Zosano Pharma	0.00%	0.00%	0.00%	0.00%	0.00%

A.I. Pioneer Issues Urgent Warning to Americans (Ad)

According to one early A.I. pioneer: “You can either use this as an unfair advantage to grow your wealth, or you can let it ravage your retirement savings. There’s no middle option.”

Click here to learn more while there’s still time.

MarketRank™

Company	Overall Score	Analyst's Opinion	Short Interest Score	Dividend Strength	ESG Score	News and Social Media Sentiment	Company Ownership	Earnings & Valuation
DMAC DiaMedica Therapeutics	0.971 of 5 stars	3.5	3.0	0.0	0.0	1.4	0.0	0.0
EVFM Evofem Biosciences	N/A	N/A	N/A	N/A	N/A	N/A	N/A	N/A
REPH Recro Pharma	N/A	N/A	N/A	N/A	N/A	N/A	N/A	N/A
RTTR Ritter Pharmaceuticals	N/A	N/A	N/A	N/A	N/A	N/A	N/A	N/A
ZSAN Zosano Pharma	N/A	N/A	N/A	N/A	N/A	N/A	N/A	N/A

Analyst Ratings

Company	Consensus Rating Score	Consensus Rating	Consensus Price Target	% Upside from Current Price
DMAC DiaMedica Therapeutics	3.00	Buy	$7.00	177.78% Upside
EVFM Evofem Biosciences	2.00	Hold	N/A	N/A
REPH Recro Pharma	N/A	N/A	N/A	N/A
RTTR Ritter Pharmaceuticals	N/A	N/A	N/A	N/A
ZSAN Zosano Pharma	N/A	N/A	N/A	N/A

Current Analyst Ratings

Latest RTTR, EVFM, REPH, DMAC, and ZSAN Analyst Ratings

Date	Company	Brokerage	Action	Rating	Price Target	Details
3/21/2024	DMAC DiaMedica Therapeutics	Craig Hallum Subscribe to MarketBeat All Access for the recommendation accuracy rating	Lower Price Target	Buy ➝ Buy	$11.00 ➝ $8.00
3/21/2024	DMAC DiaMedica Therapeutics	Oppenheimer Subscribe to MarketBeat All Access for the recommendation accuracy rating	Reiterated Rating	Outperform ➝ Outperform	$7.00 ➝ $6.00

(Data available from 4/18/2021 forward. View 10+ years of historical ratings with our analyst ratings screener.)

Sales & Book Value

Company	Annual Revenue	Price/Sales	Cashflow	Price/Cash	Book Value	Price/Book
DMAC DiaMedica Therapeutics	N/A	N/A	N/A	N/A	$1.35 per share	N/A
EVFM Evofem Biosciences	$18.22M	0.05	$1.56 per share	0.01	($2.64) per share	-0.01
REPH Recro Pharma	$75.36M	0.00	N/A	N/A	$0.90 per share	0.00
RTTR Ritter Pharmaceuticals	N/A	N/A	N/A	N/A	$0.10 per share	N/A
ZSAN Zosano Pharma	$790K	0.00	N/A	N/A	$9.74 per share	0.00

Profitability & Earnings

Company	Net Income	EPS	Trailing P/E Ratio	Forward P/E Ratio	P/E Growth	Net Margins	Return on Equity (ROE)	Return on Assets (ROA)	Next Earnings Date
DMAC DiaMedica Therapeutics	-$19.38M	-$0.62	N/A	∞	N/A	N/A	-40.07%	-37.90%	5/20/2024 (Estimated)
EVFM Evofem Biosciences	$52.98M	-$7.62	N/A	∞	N/A	290.81%	-90.20%	331.20%	4/26/2024 (Estimated)
REPH Recro Pharma	-$11.37M	-$0.31	N/A	N/A	N/A	-15.15%	-56.66%	-11.14%	N/A
RTTR Ritter Pharmaceuticals	-$10.13M	N/A	N/A	∞	N/A	N/A	N/A	-162.05%	N/A
ZSAN Zosano Pharma	-$29.92M	-$14.50	N/A	∞	N/A	-8,375.11%	-177.06%	-119.14%	N/A

Latest RTTR, EVFM, REPH, DMAC, and ZSAN Earnings

Date	Quarter	Company	Consensus Estimate	Reported EPS	Beat/Miss	Gap EPS	Revenue Estimate	Actual Revenue	Details
3/27/2024	Q4 2023	EVFM Evofem Biosciences	N/A	-$0.44	-$0.44	-$0.44	N/A	$4.84 million
3/20/2024	N/A	DMAC DiaMedica Therapeutics	-$0.14	-$0.14	N/A	-$0.14	N/A	N/A

Dividends

Company	Annual Payout	Dividend Yield	3-Year Dividend Growth	Payout Ratio	Years of Consecutive Growth
DMAC DiaMedica Therapeutics	N/A	N/A	N/A	N/A	N/A
EVFM Evofem Biosciences	N/A	N/A	N/A	N/A	N/A
REPH Recro Pharma	N/A	N/A	N/A	N/A	N/A
RTTR Ritter Pharmaceuticals	N/A	N/A	N/A	N/A	N/A
ZSAN Zosano Pharma	N/A	N/A	N/A	N/A	N/A

Debt

Company	Debt-to-Equity Ratio	Current Ratio	Quick Ratio
DMAC DiaMedica Therapeutics	N/A	19.27	19.27
EVFM Evofem Biosciences	N/A	0.13	0.10
REPH Recro Pharma	2.27	3.24	2.74
RTTR Ritter Pharmaceuticals	N/A	3.67	3.67
ZSAN Zosano Pharma	N/A	1.61	1.61

Ownership

Institutional Ownership

Company	Institutional Ownership
DMAC DiaMedica Therapeutics	10.12%
EVFM Evofem Biosciences	0.22%
REPH Recro Pharma	62.34%
RTTR Ritter Pharmaceuticals	0.84%
ZSAN Zosano Pharma	N/A

Insider Ownership

Company	Insider Ownership
DMAC DiaMedica Therapeutics	7.20%
EVFM Evofem Biosciences	0.21%
REPH Recro Pharma	14.20%
RTTR Ritter Pharmaceuticals	15.40%
ZSAN Zosano Pharma	2.40%

Miscellaneous

Company	Employees	Shares Outstanding	Free Float	Optionable
DMAC DiaMedica Therapeutics	18	37.96 million	35.23 million	Optionable
EVFM Evofem Biosciences	35	53.96 million	53.85 million	Not Optionable
REPH Recro Pharma	185	56.42 million	48.41 million	Optionable
RTTR Ritter Pharmaceuticals	7	46.15 million	N/A	Not Optionable
ZSAN Zosano Pharma	40	4.90 million	4.78 million	Not Optionable

RTTR, EVFM, REPH, DMAC, and ZSAN Headlines

Source	Headline
	HOOK HOOKIPA Pharma Inc. seekingalpha.com - April 12 at 10:11 PM
	Nachrichten - Weitere Nachrichten wallstreet-online.de - January 9 at 2:39 PM
	LISTEN: Supreme Court hears arguments on legality of Purdue Pharma bankruptcy plan pbs.org - December 6 at 7:44 AM
	Der Börsen-Tag: Diese US-Aktie stürzte nachbörslich ab n-tv.de - August 22 at 3:36 PM
	East Bay Business News bizjournals.com - May 18 at 9:49 PM
	Mankind Pharma IPO opens on April 25, listing scheduled for May 9 moneycontrol.com - April 27 at 4:20 PM
	Astellas Pharma forbes.com - April 6 at 12:00 PM
	Giiant Pharma Receives Financial Support From the US Crohn’s and Colitis Foundation finance.yahoo.com - February 5 at 12:11 PM
	FTC asks court to hold 'pharma bro' Martin Shkreli in contempt for failing to abide by orders washingtonexaminer.com - January 23 at 3:25 PM
	Zosano Pharma Corporation (ZSANQ) ca.finance.yahoo.com - November 5 at 6:33 PM
	Now bankrupt, Zosano sells off its drug delivery tech that once enticed Novo Nordisk, Eli Lilly endpts.com - October 13 at 11:22 AM
	Bankrupt Zosano Sells Its Drug Delivery Tech That Once Partnered With Pharma Giants msn.com - October 12 at 2:32 PM
	Bankrupt Zosano Pharma Says Unsecured Creditors Will Recoup 28% of Claims marketwatch.com - August 28 at 7:45 PM
	East Bay migraine patch developer Zosano closes sale in bankruptcy court for $1 million bizjournals.com - August 27 at 4:10 PM
	Zosano Pharma Corp (ZSANQ) investing.com - August 25 at 12:28 AM
	East Bay company promised drug-coated microneedle patches. Now it could be sold in bankruptcy court for just $1M bizjournals.com - July 26 at 8:27 PM
	A Fremont company promised drug-coated microneedle patches. Now it could be sold in bankruptcy court for just $1M. bizjournals.com - July 26 at 8:27 PM
	Zosano Pharma Corporation [ZSAN] stock Initiated by Maxim Group analyst, price target now $8 dbtnews.com - June 3 at 11:27 AM
	Zosano Pharma Shares Slide to New Depths After Chapter 11 Filing >ZSAN marketwatch.com - June 2 at 3:26 PM
	Why Zosano Pharma Shares Are Getting Hammered Today msn.com - June 2 at 3:26 PM
	Zosano Pharma files for Chapter 11 bankruptcy protection; shares plummet 46% seekingalpha.com - June 2 at 10:26 AM
	Cash-Strapped Zosano Pharma Files for Chapter 11 Bankruptcy >ZSAN marketwatch.com - June 2 at 10:26 AM
	East Bay migraine patch developer files for bankruptcy bizjournals.com - June 2 at 10:26 AM
	Zosano Pharma Files Voluntary Petition for Relief Under Chapter 11 finance.yahoo.com - June 2 at 10:26 AM

New MarketBeat Followers Over Time

Media Sentiment Over Time

Company Descriptions

DiaMedica Therapeutics

NASDAQ:DMAC

DiaMedica Therapeutics Inc., a clinical stage biopharmaceutical company, focuses on improving the lives of people suffering from serious diseases with a focus on acute ischemic stroke. The company develops treatments for neurological disorders and cardio-renal disease. Its lead candidate is DM199, a pharmaceutically active recombinant form of the kallikrein-1 protein for the treatment of acute ischemic stroke and other vascular diseases. It is also developing DM300 that is in preclinical stage of development for the treatment of inflammatory diseases. The company was formerly known as DiaMedica Inc. and changed its name to DiaMedica Therapeutics Inc. in December 2016. DiaMedica Therapeutics Inc. was incorporated in 2000 and is headquartered in Minneapolis, Minnesota.

Evofem Biosciences

NASDAQ:EVFM

Evofem Biosciences, Inc., a biopharmaceutical company, develops and commercializes various products to address unmet needs in women's sexual and reproductive health. Its commercial product is Phexxi, a vaginal gel for the prevention of pregnancy. The company is also involved in the development of EVO100 for the prevention of chlamydia and gonorrhea in Women; and EVO200 for the prevention of recurrent bacterial vaginosis. Evofem Biosciences, Inc. is headquartered in San Diego, California.

Recro Pharma

NASDAQ:REPH

Recro Pharma, Inc. is a pharmaceutical company, which engages in the contract development and manufacturing organization (CDMO). The firm offers integrated solutions for formulation, analytical services, regulatory support, manufacturing and packaging of both commercial and development stage oral solid dose drug products. The company was founded by Geraldine A. Henwood and Thomas F. Henwood on November 15, 2007 and is headquartered in Exton, PA.

Ritter Pharmaceuticals

NASDAQ:RTTR

Ritter Pharmaceuticals, Inc. develops and sells novel therapeutic products that modulate the human gut microbiome to treat gastrointestinal diseases. Its lead product candidate is RP-G28, a novel microbiome modulator, which has completed Phase 2b clinical trial for the reduction of symptoms associated with lactose intolerance. The company's product, RP-G28 is designed to stimulate the growth of lactose-metabolizing bacteria in the colon, thereby adapting the gut microbiome to assist in digesting the lactose that reaches the large intestine. The company was formerly known as Ritter Natural Sciences, LLC and changed its name to Ritter Pharmaceuticals, Inc. in September 2008. Ritter Pharmaceuticals, Inc. was founded in 2004 and is headquartered in Los Angeles, California.

Zosano Pharma

NASDAQ:ZSAN

Zosano Pharma Corporation, a clinical stage biopharmaceutical company, focuses on providing therapeutics and other bioactive molecules to patients suffering from migraine using its transdermal microneedle system. Its lead product candidate is Qtrypta (M207), a proprietary formulation of zolmitriptan used for the acute treatment of migraine. The company was founded in 2006 and is headquartered in Fremont, California.

Get 30 Days of MarketBeat All Access Free

Best-in-Class Portfolio Monitoring
View the latest news, buy/sell ratings, SEC filings and insider transactions for your stocks. Compare your portfolio performance to leading indices and get personalized stock ideas based on your portfolio.
Stock Ideas and Recommendations
Get daily stock ideas from top-performing Wall Street analysts. Get short term trading ideas from the MarketBeat Idea Engine. View which stocks are hot on social media with MarketBeat's trending stocks report.
Advanced Stock Screeners and Research Tools
Identify stocks that meet your criteria using seven unique stock screeners. See what's happening in the market right now with MarketBeat's real-time news feed. Export data to Excel for your own analysis.

Start Your 30-Day Free Trial